US · Healthcare · Medical Devices
EPS came in at -0.14 against a street estimate of -0.28 — a beat of 50.0%.
Analysts rate Glaukos Corp a buy (12 buy, 2 hold, 1 sell out of 15) with an average price target of $193.62.
| Fund | Stake |
|---|---|
| BlackRock Inc | 15.41% |
| HHG PLC | 9.07% |
| PRIMECAP Management Company | 5.71% |
| Vanguard Portfolio Management, LLC | 5.44% |
| Vanguard Capital Management, LLC | 4.25% |
| State Street Corp | 3.70% |
| Ameriprise Financial Inc | 2.73% |
| Citadel Advisors Llc | 2.45% |
| Document | Date |
|---|---|
| Quarterly report · Q2 2026 | 2026-07-29 |
| Results announced · Q3 2026 | 2026-07-29 |
| Shareholder vote results · Q2 2026 | 2026-06-03 |
| Reg FD disclosure · Q2 2026 | 2026-05-04 |
| Quarterly report · Q1 2026 | 2026-04-30 |
| Results announced · Q2 2026 | 2026-04-29 |
| Proxy statement · Q2 2026 | 2026-04-16 |
| Annual report FY2025 | 2026-02-23 |
Readable in the app.
| Announcement | Date |
|---|---|
| Raised 2026 full-year net sales guidance to $680-700 million Glaukos, an eye disease pharmaceutical company, reported strong Q2 2026 results that exceeded expectations. Net sales hit a record $185.6 million, up 50% year-over-year, driven primarily by | 2026-07-29 |
| Raised 2026 net sales guidance to $620-$635 million Glaukos Corporation, an eye care company, reported strong Q1 2026 results that exceeded expectations. Net sales hit a record $150.6 million, up 41% year-over-year, driven primarily by glauco | 2026-04-29 |
Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Glaukos Corp — free to start.
Google PlayApp StoreData updated 2026-08-05.